Your session is about to expire
← Back to Search
Axitinib for Alveolar Soft Part Sarcoma
Study Summary
This trial will test if the drugs Axitinib and Pembrolizumab can work together to slow tumor growth, as well as to observe any side effects of the combination treatment.
- Alveolar Soft Part Sarcoma
- Soft Tissue Sarcoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people have signed up for this research project?
"This particular study is not currently enrolling patients; however, it was updated as recently as October 20th, 2022. There are 461 other clinical trials for sarcoma and 1043 for Pembrolizumab that are actively seeking participants."
What is the primary purpose of this experiment?
"The sponsor of this clinical trial, Merck Sharp & Dohme LLC reports that the primary outcome being measured over a 3 month period is percentage of patients who achieve progression-free survival (PFS) at 3 months. Additionally, this study will measure secondary outcomes such as percentage of patients who respond to treatment with complete response (CR), partial response (PR), or stable disease (SD) using RECIST 1.1., overall survival(OS), and number of participants experiencing serious adverse events (SAEs), dose-limiting toxicities, and grade 3 or higher treatment emergent adverse events . Treatment emergent adverse events are those"
Has the Food and Drug Administration cleared Pembrolizumab for general use?
"While Phase 2 trials don't have data supporting efficacy, there is some evidence that Pembrolizumab is safe. Consequently, our estimation at Power ranks it as a 2."
What are the top conditions that Pembrolizumab helps to treat?
"Pembrolizumab is an immunotherapy drug that can be used to treat patients with malignant neoplasms, unresectable melanoma, and microsatellite instability high."
Are participants still being sought for this research?
"Unfortunately, this trial is not currently looking for new patients. Although, it's worth noting that the original posting date was April 19th, 2016 and the latest update occurred on October 20th, 2022. There are 461 other trials actively enrolling sarcoma patients and 1043 Pembrolizumab trials with open participation at this time."
What is the medical research surrounding Pembrolizumab?
"As of now, there are 1,043 active clinical trials for Pembrolizumab with 125 in Phase 3. Most of the Pembrolizumab trials are taking place in Houston, Texas; however, there are a total of 36997 locations running these sorts of tests."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger